Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Profiles of patients with TAK and healthy controls

From: A novel susceptibility locus in the IL12B region is associated with the pathophysiology of Takayasu arteritis through IL-12p40 and IL-12p70 production

  Risk group
(n = 31)
Non-risk group
(n = 13)
Healthy controls
(n = 19)
P value
Age (years) 48.1 ± 14.6 40.3 ± 12.1 35.4 ± 9.3 <0.01a
Sex (male/female) 1/30 0/11 1/18 1.00b
Duration of disease (years) 16.8 ± 11.4 15.8 ± 11.1 0.97c
Average dose of glucocorticoids (mg/day) 6.3 ± 3.5 6.3 ± 4.0 0.64c
Average CRP (mg/dL) 0.43 ± 0.77 0.14 ± 0.21 0.052c
Average ESR (mm/h) 22.6 ± 17.7 20.4 ± 20.9 0.69c
Use of immunosuppressants 8/31 (25.8%) 4/13 (30.8%) 0.73b
Use of biologics 2/31 (6.5%) 0/13 (0%) 1.00b
  1. Values are average ± standard deviation or number of patients. Immunosuppressants: methotrexate (n = 6; n = 4 in the risk group and 2 in the non-risk group) and azathioprine (n = 6; n = 4 in the risk group and 2 in the non-risk group). Biologics: tocilizumab (n = 2)
  2. TAK Takayasu arteritis, CRP C-reactive protein, ESR erythrocyte sedimentation rate
  3. aStatistical analysis performed by one-way analysis of variance.
  4. bStatistical analysis performed by Fisher’s exact test
  5. cStatistical analysis performed by Welch’s t test